Drug class
Erythropoiesis-stimulating agent (ESA); recombinant human erythropoietin biologic
Mechanism of action
Binds erythropoietin receptors on erythroid progenitor cells in bone marrow, stimulating survival, proliferation and differentiation of erythroid precursors and increasing red blood cell production.
General use cases
- Treatment of anaemia associated with chronic kidney disease in selected patients
- Treatment of zidovudine-associated anaemia in selected patients with HIV infection
- Treatment of anaemia in selected patients with non-myeloid malignancies receiving myelosuppressive chemotherapy
- Reduction of allogeneic red blood cell transfusion requirements in selected patients undergoing elective, non-cardiac, non-vascular surgery; indications are specific to the epoetin product label
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
